Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Posttranslationally modified self-peptides promote hypertension in mouse models
Nathaniel Bloodworth, … , Jens Meiler, David G. Harrison
Nathaniel Bloodworth, … , Jens Meiler, David G. Harrison
Published August 15, 2024
Citation Information: J Clin Invest. 2024;134(16):e174374. https://doi.org/10.1172/JCI174374.
View: Text | PDF
Research Article Cardiology Immunology

Posttranslationally modified self-peptides promote hypertension in mouse models

  • Text
  • PDF
Abstract

Posttranslational modifications can enhance immunogenicity of self-proteins. In several conditions, including hypertension, systemic lupus erythematosus, and heart failure, isolevuglandins (IsoLGs) are formed by lipid peroxidation and covalently bond with protein lysine residues. Here, we show that the murine class I major histocompatibility complex (MHC-I) variant H-2Db uniquely presents isoLG-modified peptides and developed a computational pipeline that identifies structural features for MHC-I accommodation of such peptides. We identified isoLG-adducted peptides from renal proteins, including sodium glucose transporter 2, cadherin 16, Kelch domain–containing protein 7A, and solute carrier family 23, that are recognized by CD8+ T cells in tissues of hypertensive mice, induce T cell proliferation in vitro, and prime hypertension after adoptive transfer. Finally, we find patterns of isoLG-adducted antigen restriction in class I human leukocyte antigens that are similar to those in murine analogs. Thus, we have used a combined computational and experimental approach to define likely antigenic peptides in hypertension.

Authors

Nathaniel Bloodworth, Wei Chen, Kuniko Hunter, David Patrick, Amy Palubinsky, Elizabeth Phillips, Daniel Roeth, Markus Kalkum, Simon Mallal, Sean Davies, Mingfang Ao, Rocco Moretti, Jens Meiler, David G. Harrison

×

Figure 7

IsoLG-adducted peptides are preferentially displayed by certain HLA molecules.

Options: View larger image (or click on image) Download as PowerPoint
IsoLG-adducted peptides are preferentially displayed by certain HLA mole...
(A) Treating K562 cells expressing single HLA alleles with tBHP induces a significant increase in the HLA-IsoLG FRET proximity mean fluorescence intensity (MFI) for all alleles screened, excepting the HLA-null control. However, there are certain alleles with significantly higher FRET MFI compared with the lowest measured in each allele class (A–C) (n = 4, mean ± SD). *P < 0.05 vs. lowest average MFI for corresponding allele class by 2-way ANOVA and Holm-Šidák post hoc test. (B) Treatment with the dicarbonyl scavenger ethyl-2-HOBA significantly reduces FRET MFI compared with tBHP-only-treated cells (n = 4). #P < 0.05 vs. corresponding tBHP-treated group by 2-way ANOVA with Holm-Šidák post hoc test. (C) Example FRET signal for all HLA alleles tested. “High-presenting” HLA-A and HLA-B alleles are highlighted in blue.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts